Obesity is associated with a metabolic imbalance that produces increased adipose tissue mass caused by a combination of hypertrophy and hyperplasia of adipocytes.Importantly, adipose tissue is itself a critical regulator of systemic metabolism, which suggests that modulation of adipogenesis should have a greater systemic impact than merely altering adipose tissue mass.Adipocytes originate from pluripotent progenitor cells (precursor stem cells) characteristic of the adipocyte lineage.A group of factors and cytckines, not fully defined, initiate a cascade of differentiation processes in which a stem cell commits to a specific lineage, for example, to become a preadipocyte.Further signals continue the progression by inducing proliferation and finally differentiation into lipid-laden adipocytes.Myostatin, also known as growth and differentiation factor 8 (GDF8), is a member of the TGFbeta super family.Myostatin is currently thought to inhibit the recruitment of mesenchyme stem cells away from musculoskeletal pathway, inhibiting myogenesis and promotes the differentiation of multipotent mesenchymal cells into the adipogenic lineage.A newly discovered bio-engineered peptide-a proprietary amino acid complex developed based on the follistatin protein-is capable of inducing a pharmaceutical grade effect in human muscle and adipose fat function.